CTOs on the Move

Foghorn Therapeutics

www.foghorntx.com

 
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.foghorntx.com
  • 500 Technology Square Suite 700
    Cambridge, MA USA 02139
  • Phone: 617.586.3100

Executives

Name Title Contact Details
Dan Dinu
Head Of Information Technology Profile

Funding

Foghorn Therapeutics raised $61M on 05/12/2019

Similar Companies

Trualta

We empower the most underserved stakeholder in the healthcare system – the family caregiver. While training programs exist for home health aides or nurses to help manage care of the elderly, family members, who provide 80%+ of care to loved ones aging-in-place, have limited access to training. For example, actionable education like how to prevent falls in the house, safely transfer from a bed or chair, or manage difficult behaviour when a loved one has dementia. Recognizing that this content exists but isn`t available to families, Trualta adapted professional-level healthcare training for the family member audience. We deliver the training via an informal and interactive online learning environment, and tailor the learning to each caregiver`s situation. The program incentivizes engagement with a rewards system, and users can redeem rewards for helpful products and services. Our customers, healthcare payers and providers in Canada & the US, offer Trualta at point-of-care to better enable families to transition aging loved ones from hospital to home, and sustain independent living. Through clinical validation studies in the US and Canada, we are linking participation in Trualta`s program to improved outcomes and reduced costs. We are a proud resident company of the Biomedical Zone in downtown Toronto and the Invest Ottawa Accelerator program. If you are passionate about educating and enabling families to improve care for our aging population, drop us a note at info@trualta.com – we`d love to hear from you.

Dako

DAKO is a fully integrated, global provider of cancer diagnostic and research products for pathology and oncology. The Company's products utilize antibodies, nucleic acid probes, and proprietary detection technologies to identify specific

Healthline.com

Healthline.com is a Adrian, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fibrocell Science

Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.

PharmaNet Development Group

PharmaNet is an international drug development company employing about 1,500 professionals worldwide.